Aengus Tran: Scaling Clinician-Led AI from Australian Healthtech into Global Diagnostics
Dr Aengus Tran’s leadership story sits at the intersection of medicine, artificial intelligence and the global shortage of clinical expertise. Harrison.ai identifies him as CEO and co-founder, and the company says it was founded in 2018 by Aengus and Dimitry Tran with the ambition of using technology to create healthcare impact at exponential scale.
That origin is important because Harrison.ai was not created as a generic AI company looking for a healthcare use case. It was built around a specific healthcare problem: the world does not have enough trained clinicians to meet rising diagnostic demand. Harrison.ai’s public materials describe its radiology and pathology tools as medical imaging diagnostic support and workflow optimisation solutions designed to help clinicians deliver faster and more accurate diagnoses.
In his current role, Tran’s major achievement has been turning that mission into a clinically deployed international business. Harrison.ai says its technology is deployed at more than 1,000 sites across four continents, with more than 3,400 clinicians using its solutions and more than 6.7 million medical imaging cases analysed. It also says its solutions have regulatory clearance in more than 40 countries and distribution across 15 countries.
Those numbers matter because healthtech is a sector where ambition often runs ahead of implementation. AI healthcare companies can attract attention with research claims, but the harder test is whether their tools are cleared, adopted, integrated into workflows and trusted by clinicians. Tran’s current leadership impact is that Harrison.ai has moved meaningfully into that harder category.
Capital raising has also been a major outcome. In February 2025, Harrison.ai announced a US$112 million Series C round to accelerate expansion into the United States, fund its product roadmap and support growth across the UK, EMEA and APAC. The company said the round was co-led by Aware Super, ECP and Horizons Ventures, with new investors including Australia’s National Reconstruction Fund Corporation, Ord Minnett and Wollemi Capital Group, and that total capital raised exceeded US$240 million.
That raise is significant not only because of its size, but because of what it says about Tran’s ability to position the company globally. Healthcare AI is capital intensive: it requires clinical validation, regulatory work, specialist engineering, distribution partnerships and patient-safety credibility. Raising that level of capital gives Harrison.ai the resources to move from Australian success into international competition.
One of Tran’s most important strategic moves has been building through partnerships with major healthcare operators. Harrison.ai formed Annalise.ai with I-MED Radiology Network in 2020 to develop radiology AI solutions. Sonic Healthcare later announced a joint venture with Harrison.ai to develop and commercialise pathology AI solutions, noting that Harrison.ai already had a track record in imaging and IVF, and that Annalise CXR had been developed and commercialised in 18 months as a comprehensive clinical decision-support solution for chest X-rays.
That partnership model reveals a lot about Tran’s leadership style. Instead of trying to disrupt clinicians from the outside, Harrison.ai has embedded itself with clinical partners that already understand real-world diagnostic workflows. That is strategically important. Medical AI cannot succeed merely by being technically impressive; it must fit into how radiologists, pathologists and hospitals actually work.
The unification of Harrison.ai and Annalise.ai into one company marked another major step. Harrison.ai said the combined business would be led by Aengus Tran as CEO, with Dimitry Tran as Deputy CEO, and that the move was intended to accelerate global growth and adoption. The company said Harrison.ai solutions were available in more than 40 countries, deployed at more than 1,000 customer sites globally, including more than 40 NHS Trusts and all public emergency departments in Hong Kong, and had impacted more than 7 million patient lives to date.
That consolidation is a meaningful leadership move because it simplifies the story. Rather than having separate brand and venture structures for radiology and platform development, Harrison.ai can now present a more unified global healthcare AI company. For customers, regulators and investors, that clarity matters.
Tran’s past experience is also central to the story. As a doctor and technologist, he brings clinical understanding to a field often dominated by either pure software founders or traditional medical device executives. Harrison.ai’s own materials emphasise that the company is led by practicing clinicians and grounded in real-world healthcare experience. That clinician-led identity is not just branding; it shapes the company’s credibility in a sector where mistakes have human consequences.
The company’s early technical achievements also show how quickly Tran and his team were able to move from concept to application. Sonic Healthcare’s 2021 announcement noted that Harrison.ai and I-MED formed Annalise.ai in early 2020 and that Annalise CXR was developed and commercialised in just 18 months. It also stated that Sonic was implementing the solution at more than 100 radiology clinics around Australia.
That speed is impressive because healthcare validation is not like consumer software iteration. Clinical products must be designed, tested, cleared and deployed with care. Tran’s achievement has been to combine start-up urgency with enough clinical discipline to enter real diagnostic environments.
